Comparing of Ophthotech Corporation (OPHT) and Its Competitors

Ophthotech Corporation (NASDAQ:OPHT) is a company in the Biotechnology industry and that’s how we contrast it to its rivals. The comparing will be based on the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Institutional and Insider Ownership

65.6% of Ophthotech Corporation’s shares are held by institutional investors. Comparatively, 52.39% of all Biotechnology’s companies shares are held by institutional investors. 0.2% of Ophthotech Corporation shares are held by company insiders. Comparatively, 8.89% of all Biotechnology companies shares are held by company insiders.

Profitability

Table 1 has Ophthotech Corporation and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ophthotech Corporation 0.00% 688.20% 97.30%
Industry Average 468.58% 80.16% 25.47%

Earnings and Valuation

The following data compares Ophthotech Corporation and its rivals’ net income, top-line revenue and valuation.

Net Income Gross Revenue Price/Earnings Ratio
Ophthotech Corporation 63.09M N/A 0.00
Industry Average 14.75M 3.15M 89.01

Analyst Recommendations

Table 3 provides breakdown of current ratings for Ophthotech Corporation and its rivals.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ophthotech Corporation 0 0 0 0.00
Industry Average 1.28 2.04 2.89 2.79

The potential upside of the peers is 137.44%.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Ophthotech Corporation and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ophthotech Corporation 6.85% 23.81% -12.36% -38.82% -42.86% 30%
Industry Average 7.88% 20.03% 31.47% 42.06% 73.21% 38.48%

For the past year Ophthotech Corporation has weaker performance than Ophthotech Corporation’s competitors.

Liquidity

Ophthotech Corporation has a Current Ratio of 13 and a Quick Ratio of 13. Competitively, Ophthotech Corporation’s peers Current Ratio is 7.48 and has 7.37 Quick Ratio. Ophthotech Corporation has better ability to pay short and long-term obligations than Ophthotech Corporation’s competitors.

Risk and Volatility

Ophthotech Corporation has a beta of 1.51 and its 51.00% more volatile than Standard and Poor’s 500. In other hand, Ophthotech Corporation’s peers have beta of 1.91 which is 90.82% more volatile than Standard and Poor’s 500.

Dividends

Ophthotech Corporation does not pay a dividend.

Summary

Ophthotech Corporation’s competitors show that they’re better in 3 of the 4 indicators compared to the company itself.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.